Birch Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Birch Allergy Market Outlook

Thelansis’s “Birch Allergy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Birch Allergy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Birch Allergy Overview

Birch belongs to the order Fagales and the family Betulaceae, which are widely distributed across the United States. Numerous species of birch trees can be found throughout the country, contributing to allergies. The European white birch (Betula pendula) and River birch (Betula nigra) are the two most prevalent varieties. Birch pollen is a significant allergen inhaled from the air, particularly in the northern temperate region. This pollen often leads to allergic rhinitis, asthma, and allergies to certain foods associated with pollen exposure. The prevalence of sensitivity to birch pollen is approximately 8-16% in the general population and ranges from 7-57% among patients attending various allergy clinics. The International Allergen Nomenclature Sub-committee has recognized seven allergens associated with birch pollen, with Bet v 1 being the primary allergen. To enhance diagnostic accuracy, component-resolved testing can differentiate broad cross-reactivity and prevent false-positive diagnoses of pollen allergies attributed to pan-allergens like Bet v 2, 4, or Bet v 7, from genuine birch allergies involving the main allergen Bet v 1-specific IgE. Oral Allergy Syndrome (OAS) symptoms may manifest as:

• Tingling or itching in the mouth
• Hives around the mouth
• Irritation or discomfort in the throat
• Swelling of the lips, mouth, tongue, or throat

Individuals displaying allergic reactions to birch pollen exhibit notably higher levels of serum anti-Bet v 1 IgE compared to individuals with birch sensitivity who remain asymptomatic. Elevated IgE levels related to Bet v 1 are also predictive of oral allergy syndrome following consuming fruits from the Rosaceae family, nuts, or vegetables from the Apiaceae family, which contain homologous allergens cross-reactive with birch allergens.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: